The use of the monoclonal antibody partially inhibited tumour growth and this inhibitory effect was increased when the anti-CTLA4 antibody was combined with a low-dose cyclophosphamide (CTX) regimen, but not when the anti-CTLA4 antibody was combined with high-dose injection of CTX plus a low oral dose of CTX [13]. Here, CTLA4 is linked to neoplasm.